Dr. Bishoy M. Faltas· @FaltasLab · X·· 20 小时前评分70
正文
暂无中文译文，显示英文原文。
Congratulations @tompowles1 and team! EVD #VOLGA #ESMO26
0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgPresented at #ESMO26: In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: https://nej.md/4z7dQFm @myESMO在 X 查看被引用的帖子
来源：Dr. Bishoy M. Faltas · x.com